CompletedNot Applicable

SAHaRA: A Randomized Controlled Trial

United States, Australia742 participantsStarted 2018-02-12

Plain-language summary

The SAHaRA trial will clarify the role of treating anemia with Red Blood Cell (RBC) transfusion in a unique and vulnerable patient population, and determine whether that impacts on functional outcomes and mortality. It will guide best practice standards and clarify the optimal RBC transfusion strategy in patients with aSAH.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥18 years old at time of SAH
✓. First ever episode of aneurysmal SAH
✓. Diagnosis of aSAH as confirmed by treating physician (eg: neurosurgeon or neuro- interventionalist) and supported by blood in subarachnoid space (e.g. cranial imaging or cerebrospinal fluid positive for xanthochromia, surgical visualization) that is the result of a ruptured aneurysm (e.g. direct visualization, cranial imaging or catheter angiogram)
✓. Hb ≤100g/L within 10 days following aSAH (defined by first day of hospital presentation)

Exclusion criteria

✕. Physician and or family decision to withdraw/withhold active medical care at time of enrolment
✕. Active bleeding with hemodynamic instability at time of enrolment
✕. Patients with contraindication or known objection to blood transfusions
✕. SAH due to mycotic aneurysm, infundibulum and vascular malformations.

What they're measuring

Modified Rankin Scale (mRS)

Timeframe: 12 months post

Trial details

NCT IDNCT03309579

SponsorOttawa Hospital Research Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-07-10

View on ClinicalTrials.gov More Subarachnoid Hemorrhage, Aneurysmal trials